SELLAS Life Sciences (SLS) Capital Expenditures (2010 - 2016)
SELLAS Life Sciences (SLS) reported Capital Expenditures of -$6000.0 for Q4 2016, up 98.43% year-over-year from -$3023.8 in Q1 2016, and down 200.0% on a QoQ basis from $6000.0 in Q1 2016.
SELLAS Life Sciences (SLS) has 6 years of Capital Expenditures data on file, last reported at -$6000.0 in Q4 2016.
- Quarterly Capital Expenditures rose 98.43% year-over-year to -$6000.0 in Q4 2016, while the trailing twelve-month figure through Sep 2016 was -$375000.0 (down 169.06% YoY) and the FY2015 annual result came in at $153000.0, up 168.42% from the prior year.
- Capital Expenditures declined to -$6000.0 in Q4 2016 per SLS's latest filing, from $6000.0 in the prior quarter.
- Across five years, Capital Expenditures topped out at $500000.0 in Q1 2015 and bottomed at -$381000.0 in Q4 2015.
- The 4-year median for Capital Expenditures is $9000.0 (2014), against an average of $7272.7.
- Peak annual rise in Capital Expenditures reached 2172.73% in 2015, while the deepest fall reached 4333.33% in 2015.
- Tracing SLS's Capital Expenditures over 4 years: stood at -$234000.0 in 2013, then jumped by 103.85% to $9000.0 in 2014, then tumbled by 4333.33% to -$381000.0 in 2015, then jumped by 98.43% to -$6000.0 in 2016.
- Per Business Quant, the three latest SLS Capital Expenditures figures stand at -$6000.0 (Q4 2016), $6000.0 (Q1 2016), and -$381000.0 (Q4 2015).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 133.40 Mn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 230.60 Mn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 21.83 Mn |
| 10 | SELLAS Life Sciences | 1.61 Bn | 1.61 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2016 | -6,000.00 |
| Dec 31, 2016 | -6,000.00 |
| Mar 31, 2016 | 6,000.00 |
| Mar 31, 2016 | 6,000.00 |
| Dec 31, 2015 | -381,000.00 |
| Dec 31, 2015 | -381,000.00 |
| Jun 30, 2015 | 34,000.00 |
| Jun 30, 2015 | 34,000.00 |
| Mar 31, 2015 | 500,000.00 |
| Mar 31, 2015 | 500,000.00 |
| Dec 31, 2014 | 9,000.00 |
| Dec 31, 2014 | 9,000.00 |
| Sep 30, 2014 | 19,000.00 |
| Sep 30, 2014 | 19,000.00 |
| Jun 30, 2014 | 7,000.00 |
| Jun 30, 2014 | 7,000.00 |
| Mar 31, 2014 | 22,000.00 |
| Mar 31, 2014 | 22,000.00 |
| Dec 31, 2013 | -234,000.00 |
| Dec 31, 2013 | -234,000.00 |
| Sep 30, 2013 | 104,000.00 |
| Sep 30, 2013 | 104,000.00 |
| Jun 30, 2011 | 13,000.00 |
| Jun 30, 2011 | 13,000.00 |
| Mar 31, 2011 | 40,000.00 |
| Mar 31, 2011 | 40,000.00 |
| Dec 31, 2010 | 41,000.00 |
| Dec 31, 2010 | 41,000.00 |
| Sep 30, 2010 | 11,000.00 |
| Sep 30, 2010 | 11,000.00 |